OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice
María Molina‐Vega, Jorge Garcı́a-Alemán, Arántzazu Sebastián-Ochoa, et al.
Endocrine (2017) Vol. 59, Iss. 2, pp. 395-401
Closed Access | Times Cited: 22
María Molina‐Vega, Jorge Garcı́a-Alemán, Arántzazu Sebastián-Ochoa, et al.
Endocrine (2017) Vol. 59, Iss. 2, pp. 395-401
Closed Access | Times Cited: 22
Showing 22 citing articles:
2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer
Laura Fugazzola, Rossella Elisei, Dagmar Führer, et al.
European Thyroid Journal (2019) Vol. 8, Iss. 5, pp. 227-245
Open Access | Times Cited: 240
Laura Fugazzola, Rossella Elisei, Dagmar Führer, et al.
European Thyroid Journal (2019) Vol. 8, Iss. 5, pp. 227-245
Open Access | Times Cited: 240
Multikinase Inhibitor Treatment in Thyroid Cancer
Ole Vincent Ancker, Marcus Krüger, Markus Wehland, et al.
International Journal of Molecular Sciences (2019) Vol. 21, Iss. 1, pp. 10-10
Open Access | Times Cited: 109
Ole Vincent Ancker, Marcus Krüger, Markus Wehland, et al.
International Journal of Molecular Sciences (2019) Vol. 21, Iss. 1, pp. 10-10
Open Access | Times Cited: 109
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era
Jaume Capdevila, Ahmad Awada, Dagmar Führer‐Sakel, et al.
Cancer Treatment Reviews (2022) Vol. 106, pp. 102380-102380
Open Access | Times Cited: 49
Jaume Capdevila, Ahmad Awada, Dagmar Führer‐Sakel, et al.
Cancer Treatment Reviews (2022) Vol. 106, pp. 102380-102380
Open Access | Times Cited: 49
How [18F]FDG-PET/CT Affects the Management of Patients with Differentiated Thyroid Carcinoma in Clinical Routines
Jonas Vogel, Julia Sekler, Brigitte Gückel, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 588-588
Open Access | Times Cited: 6
Jonas Vogel, Julia Sekler, Brigitte Gückel, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 588-588
Open Access | Times Cited: 6
Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
E Sun Paik, Tae Hyun Kim, Young‐Jae Cho, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 21
E Sun Paik, Tae Hyun Kim, Young‐Jae Cho, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 21
Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib
Pu Chen, Jianling Wang, Yao Yao, et al.
Endocrine (2024) Vol. 85, Iss. 3, pp. 1268-1277
Closed Access | Times Cited: 2
Pu Chen, Jianling Wang, Yao Yao, et al.
Endocrine (2024) Vol. 85, Iss. 3, pp. 1268-1277
Closed Access | Times Cited: 2
The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer
Fernando Jerkovich, María Gabriela García Falcone, Fabián Pitoia
Endocrine (2019) Vol. 64, Iss. 3, pp. 632-638
Closed Access | Times Cited: 18
Fernando Jerkovich, María Gabriela García Falcone, Fabián Pitoia
Endocrine (2019) Vol. 64, Iss. 3, pp. 632-638
Closed Access | Times Cited: 18
Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event
Salvatore Monti, Federica Presciuttini, Maria Grazia Deiana, et al.
Thyroid (2021)
Open Access | Times Cited: 15
Salvatore Monti, Federica Presciuttini, Maria Grazia Deiana, et al.
Thyroid (2021)
Open Access | Times Cited: 15
Personalized treatment for differentiated thyroid cancer: current data and new perspectives
Carla Colombo, Noemi Giancola, Laura Fugazzola
Minerva Endocrinology (2021) Vol. 46, Iss. 1
Closed Access | Times Cited: 13
Carla Colombo, Noemi Giancola, Laura Fugazzola
Minerva Endocrinology (2021) Vol. 46, Iss. 1
Closed Access | Times Cited: 13
The diagnostic and prognostic significance of long noncoding RNAs expression in thyroid cancer: A systematic review and meta-analysis
Jing Wei, Xiaogai Li, Ruoyu Peng, et al.
Pathology - Research and Practice (2018) Vol. 214, Iss. 3, pp. 327-334
Closed Access | Times Cited: 16
Jing Wei, Xiaogai Li, Ruoyu Peng, et al.
Pathology - Research and Practice (2018) Vol. 214, Iss. 3, pp. 327-334
Closed Access | Times Cited: 16
Body Composition and Leptin/Ghrelin Levels during Lenvatinib for Thyroid Cancer
Simone De Leo, Carla Colombo, Marta Di Stefano, et al.
European Thyroid Journal (2019) Vol. 9, Iss. 1, pp. 1-10
Open Access | Times Cited: 14
Simone De Leo, Carla Colombo, Marta Di Stefano, et al.
European Thyroid Journal (2019) Vol. 9, Iss. 1, pp. 1-10
Open Access | Times Cited: 14
Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells
Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, et al.
Endocrine (2019) Vol. 65, Iss. 1, pp. 110-120
Closed Access | Times Cited: 11
Si Hyoung Kim, Jun Goo Kang, Chul Sik Kim, et al.
Endocrine (2019) Vol. 65, Iss. 1, pp. 110-120
Closed Access | Times Cited: 11
Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells
Valentina Maggisano, Marilena Celano, Saverio Massimo Lepore, et al.
Endocrine (2019) Vol. 63, Iss. 3, pp. 545-553
Closed Access | Times Cited: 10
Valentina Maggisano, Marilena Celano, Saverio Massimo Lepore, et al.
Endocrine (2019) Vol. 63, Iss. 3, pp. 545-553
Closed Access | Times Cited: 10
Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience
Natália Treistman, Gabriela Maia Nobre, Mariana Yoshii Tramontin, et al.
Archives of Endocrinology and Metabolism (2021)
Open Access | Times Cited: 8
Natália Treistman, Gabriela Maia Nobre, Mariana Yoshii Tramontin, et al.
Archives of Endocrinology and Metabolism (2021)
Open Access | Times Cited: 8
Silencing of DJ-1 reduces proliferation, invasion, and migration of papillary thyroid cancer cells in vitro, probably by increase of PTEN expression.
Kai Qiu, Qingji Xie, Shan Jiang, et al.
PubMed (2019) Vol. 12, Iss. 6, pp. 2046-2055
Closed Access | Times Cited: 8
Kai Qiu, Qingji Xie, Shan Jiang, et al.
PubMed (2019) Vol. 12, Iss. 6, pp. 2046-2055
Closed Access | Times Cited: 8
Sorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin: A 7-Year Single-Centre Experience
Francisco Sousa Santos, Rita Santos, Valeriano Leite
European Thyroid Journal (2019) Vol. 8, Iss. 5, pp. 262-267
Open Access | Times Cited: 7
Francisco Sousa Santos, Rita Santos, Valeriano Leite
European Thyroid Journal (2019) Vol. 8, Iss. 5, pp. 262-267
Open Access | Times Cited: 7
High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer
Marta Di Stefano, Carla Colombo, Simone De Leo, et al.
European Thyroid Journal (2020) Vol. 10, Iss. 4, pp. 314-322
Open Access | Times Cited: 7
Marta Di Stefano, Carla Colombo, Simone De Leo, et al.
European Thyroid Journal (2020) Vol. 10, Iss. 4, pp. 314-322
Open Access | Times Cited: 7
Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience
Matea Pešorda
Acta Clinica Croatica (2020)
Open Access | Times Cited: 7
Matea Pešorda
Acta Clinica Croatica (2020)
Open Access | Times Cited: 7
In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology
Alexandru Opriţa, Mihaela Amelia Dobrescu, Elena Victoria Manea, et al.
Romanian Journal of Morphology and Embryology (2023) Vol. 64, Iss. 2, pp. 173-180
Open Access | Times Cited: 2
Alexandru Opriţa, Mihaela Amelia Dobrescu, Elena Victoria Manea, et al.
Romanian Journal of Morphology and Embryology (2023) Vol. 64, Iss. 2, pp. 173-180
Open Access | Times Cited: 2
Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
Anne Christine Kaae, Michael C. Kreißl, Marcus Krüger, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12217-12217
Open Access | Times Cited: 5
Anne Christine Kaae, Michael C. Kreißl, Marcus Krüger, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12217-12217
Open Access | Times Cited: 5
The role of ATP-binding cassette transporter genes in the metastatic process of epithelial thyroid carcinoma with aggressive behavior
Giovanna Revilla, Antonio Moral, José Ignacio Arias Pérez, et al.
Elsevier eBooks (2022), pp. 265-275
Closed Access
Giovanna Revilla, Antonio Moral, José Ignacio Arias Pérez, et al.
Elsevier eBooks (2022), pp. 265-275
Closed Access
Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma
延泽 刘
Advances in Clinical Medicine (2022) Vol. 12, Iss. 09, pp. 8499-8507
Closed Access
延泽 刘
Advances in Clinical Medicine (2022) Vol. 12, Iss. 09, pp. 8499-8507
Closed Access
